Kai Gruhn

Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled, phase 2 trial

Albert C. Ludolph, Joachim Schuster, Johannes Dorst et al. · The Lancet Neurology · 2018 · 78 citations · Full text

Amyotrophic Lateral Sclerosis, Neurological Disorder, Medicine +5

Increased risk of suicide under intrathecal ziconotide treatment? – A warning

Christoph Maier, Hans-Helmut Gockel, Kai Gruhn et al. · Pain · 2010 · 39 citations

Muscle imaging data in late-onset Pompe disease reveal a correlation between the pre-existing degree of lipomatous muscle alterations and the efficacy of long-term enzyme replacement therapy

Kai Gruhn, Christoph M. Heyer, Anne‐Katrin Güttsches et al. · Molecular Genetics and Metabolism Reports · 2015 · 21 citations · Full text

Excitability in somatosensory cortex correlates with motoric impairment in amyotrophic lateral sclerosis

Oliver Höffken, Alena Schmelz, Melanie Lenz et al. · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · 2019 · 16 citations

VE-cadherin and ACE: Markers for sepsis in post mortem examination?

Annette Müller, Kai Gruhn, Martina C. Herwig‐Carl et al. · Legal Medicine · 2008 · 15 citations

Cardiovascular Disease, Medicine, Inflammatory Marker +7